This year marks the 30th anniversary of MSD’s entry into the Chinese market.
As a world leader in research-based biopharmaceuticals, MSD said it will continue to “write our future” with China and use the 5th China International Import Expo to showcase its great achievements in the healthcare industry and demonstrate its long-term strength. commitment.
“China is an important part of MSD’s global growth strategy and one of our most important markets in the world,” said Anna Van Acker, President of MSD China and Senior Vice President of MSD.
“From human health to animal health, our firm commitment to bringing high-quality medicines and vaccines to China has remained unchanged for more than three decades. »
MSD’s history in China began with its transfer of hepatitis B vaccine technology to China in 1989. This transfer of technology changed the lives of tens of millions of Chinese people and served as a prelude to the relationship 30 years of MSD with China.
The company is headquartered in Shanghai, with research facilities in Beijing and Ningbo, and factories in Hangzhou, Ningbo and Tianjin, integrating R&D, manufacturing and business operations for human health and animal health. It is expected to help China address the most pressing health challenges, from prevention to treatment with vaccines, medicines and digital solutions in key areas such as diabetes, infection control, oncology and diseases. rare.
“During its 130-year history, MSD has remained deeply inspired by its core value as expressed by George Merck that ‘we try to never forget that medicine is for the people. It’s not for profit,” Van Acker said.
“In China, we are committed to providing high-quality medicines and vaccines to improve or save the lives of patients suffering from cardiovascular and metabolic diseases, infectious diseases and cancer, to name just a few areas of our deep expertise and our scientific know-how.
“As one of the key players in China’s healthcare field, MSD contributes to the robust development of medical and healthcare services in China, guiding the industry towards the Chinese government’s vision of creating a system centered on improving people’s health.
The China International Import Expo is a “grand” platform for MSD to demonstrate its ability and determination to help address significant unmet medical needs.
This is the fourth time that MSD has joined the CIIE, which is held at the National Exhibition and Convention Center.
Located at Booth 7.2A3-03 in the Medical Equipment and Healthcare Exhibition Area, the MSD China Pavilion covers 1,000 square meters, making it one of the largest exhibitors at the CIIE. At this year’s CIIE, MSD will hold more than 10 events and deal-signing ceremonies with its partners in the Chinese healthcare ecosystem, demonstrating its continued commitment to the Chinese market, building on the successes of the last three decades.
“What we want to emphasize is that we have a very comprehensive and simple strategy in place in China,” Van Acker said. The overall strategy is also included in this year’s theme “30 Years of MSD in China: Writing Our Future, Healthcare for All” that permeates the main pavilion of CIIE MSD. The stand consists of four areas corresponding to the four pillars of MSD China to accelerate progress:
• Strengthen the portfolio of cutting-edge drugs and vaccines to create effective disease prevention and treatment solutions.
• Leverage digitalization to consolidate operational efficiency and strengthen innovation and important local partnerships.
• Create a trusted platform for patient access through enhanced public awareness programs.
• Leverage the three-in-one engine of R&D, manufacturing and business operations to work with partners and write a new future for a healthier China.
Designed with the idea of a “future track” leading to the goal of “Healthy China 2030”, the MSD pavilion integrates exhibits into three dynamic tracks with the themes of “Medicine”, “Key” and “Importance”, all pronouncing like “Yao” in Chinese and reflecting different extended meanings of the beautiful Chinese character “Yao”.
“We deliberately called it ‘Writing Our Future’ and ‘Yao’ in Chinese, and it demonstrates our progress and dedication to working with partners to vigorously improve accessibility for patients and consumers, and to become a partner China’s leading trusted healthcare ecosystem,” Van Acker said.
MSD’s flagship exhibit this year is the oral antiviral drug used to treat COVID-19, molnupiravir, which was co-developed by MSD and Ridgeback Biotherapeutics.
The company has just announced a cooperative framework agreement with Sinopharm for distribution rights and exclusive import rights for molnupiravir in mainland China, so that once regulatory approval is obtained, it can potentially benefit Chinese patients. in need.
MSD will also feature a series of innovative exhibits and interactive experiences to showcase its centuries-old history, its most significant achievements in the country over the past three decades, and its remarkable growth journey alongside China’s healthcare industry. .
Through the pavilion, MSD will showcase its vision to work with partners to build an innovative, industry-leading, and sustainable healthcare ecosystem that helps China implement its “Healthy China” agenda. .
“Over the past three years, MSD has had the privilege of participating in the CIIE and witnessing China’s growing openness and partnership with the world,” Van Acker said.
“Today, MSD China stands at a crucial point between its past and its future. In our first 30 years, we have made incredible strides towards improving healthcare in the country, and we must continue to rely relentlessly on our passion for innovation and our mission to save and improve lives to move towards a better future for all.
“Through the CIIE’s world-class open platform, we look forward to advancing our journey to fulfill MSD’s long-term commitment and promise to China as we strengthen our cooperation with public organizations, medical institutions, industrial partners and other sectors of society.
“Through our innovative medical solutions and continued care, we are focused and committed to driving superior access and outcomes for patients and consumers as a trusted partner on the path to a ‘Healthy China’. “. »